By Mill Chart
Last update: Dec 6, 2023
Uncover the potential of SANOFI-ADR (NASDAQ:SNY) as our stock screener's choice for an undervalued stock. NASDAQ:SNY maintains a strong financial position and offers an appealing valuation. We'll delve into the specifics below.
ChartMill assigns a Valuation Rating to every stock. This score ranges from 0 to 10 and evaluates the different valuation aspects and compares the price to earnings and cash flows, while taking into account profitability and growth. NASDAQ:SNY scores a 8 out of 10:
Discover ChartMill's exclusive Profitability Rating, a proprietary metric that assesses stocks on a scale of 0 to 10. It takes into consideration various profitability ratios and margins, both in absolute terms and relative to industry peers. Notably, NASDAQ:SNY has achieved a 8:
A critical element of ChartMill's stock evaluation is the Health Rating, which spans from 0 to 10. This rating considers multiple health factors, including liquidity and solvency, both in absolute terms and relative to industry peers. NASDAQ:SNY has received a 7 out of 10:
ChartMill assigns a proprietary Growth Rating to each stock. The score is computed by evaluating various growth aspects, like EPS and revenue growth. We take into account the history as well as the estimated future numbers. NASDAQ:SNY was assigned a score of 5 for growth:
Our Decent Value screener lists more Decent Value stocks and is updated daily.
Our latest full fundamental report of SNY contains the most current fundamental analsysis.
This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.
NASDAQ:SNY (2/16/2024, 7:26:35 PM)After market: 46.0011 -0.18 (-0.39%)
Don't count these companies out too soon.
Sanofi and Regeneron Pharmaceuticals gain approval for their allergy medication Dupixent in Japan, making it the first country to approve the drug for the...
Although the healthcare innovation space has struggled recently, these contrarian biotech stocks now offer compelling discounts.
After a blistering hot year of biotech M&A, we’ll see more of the same in 2024. That could be great news for these hot biotech stocks.
Exploring SANOFI-ADR (NASDAQ:SNY)'s dividend characteristics.
SANOFI-ADR (NASDAQ:SNY) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
AstraZeneca&#39;s operating profits fell short of expectations, but its oncology portfolio performed well, leading to a revenue beat in Q4 2023. Read more here.
NVO stock rose after Novo Nordisk's parent, Novo Holdings, said it has agreed to buy contract manufacturer Catalent for $11.5 billion in cash.
SNY earnings call for the period ending December 31, 2023.
The company missed total sales and earnings expectations.
Sanofi, a French pharmaceutical firm, reports a net loss in Q4 2023 due to currency movements despite strong sales of Dupixent.